Fierce Pharma
AUGUST 9, 2024
With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.
MedCity News
AUGUST 9, 2024
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums. The post An Upcoming White House Decision May Jeopardize Americans’ Access to Life-Saving Drugs appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 9, 2024
As Purdue Pharma attempts to restore its image following its role in | As Purdue Pharma attempts to restore its image following its role in the U.S. opioid crisis, the Connecticut-based company has scored a win with a green light for a new overdose rescue treatment.
MedCity News
AUGUST 9, 2024
This latest eBook highlights the content of our conferences — INVEST in Chicago and INVEST Digital Health in Dallas. It spotlights talks such as Small business Education and Entrepreneurial Development funding, investor perspectives on AI, women’s health, health tech implementation, medtech trends, cybersecurity, and drug development innovation.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 9, 2024
Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged. | Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged.
MedCity News
AUGUST 9, 2024
Through a new partnership, Eleanor Health’s patients can access Thriveworks’ therapists for additional mental health support beyond their substance-use disorder, including couples and family counseling. Likewise, Thriveworks’ patients in Louisiana, Massachusetts, New Jersey, North Carolina, Ohio, Texas and Washington can receive substance-use disorder treatment from Eleanor Health.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 9, 2024
Business and compliance considerations for MSOs and PCs, the contractual structure, and general recommendations for establishing a model that runs efficiently and mitigates levels of risk The post “Friendly” PC Models: Key Contractual and Compliance Considerations appeared first on MedCity News.
PharmaVoice
AUGUST 9, 2024
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
MedCity News
AUGUST 9, 2024
It’s important to keep in mind that parents, with physician support, can beat the summer slump, particularly with planning and resources. Behavioral activation includes scheduling activities that encourage children to reconnect with environmental positive reinforcement and decrease avoidant behaviors and negative emotions. The post Children and Mental Health: Using Behavioral Activation to Combat the ‘Summer Slump’ appeared first on MedCity News.
pharmaphorum
AUGUST 9, 2024
Eli Lilly's oral tau drug fails to show efficacy in a phase 2 trial in Alzheimer's disease in another setback for the class
Pharmaceutical Technology
AUGUST 9, 2024
Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.
pharmaphorum
AUGUST 9, 2024
Eli Lilly raises guidance for 2024 by $3 billion on strong growth for tirzepatide in diabetes and obesity and improved supply capacity
PharmaTimes
AUGUST 9, 2024
In the UK, there are an estimated 11 million people living with a neurological condition
pharmaphorum
AUGUST 9, 2024
At the second attempt, the FDA has approved Citius Pharmaceuticals' Lymphir for rare lymphoma CTCL
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
PharmaTimes
AUGUST 9, 2024
The study revealed that 13% of patients have a genetic form of the neurological disease
Pharmaceutical Technology
AUGUST 9, 2024
In the past few years, there has been a significant increase in the use of GLP-1 receptor agonists as a treatment for Type 2 diabetes and obesity.
pharmaphorum
AUGUST 9, 2024
Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.The latest setback is in a phase 3 trial of MSD's anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab in small cell lung cancer (SCLC), with a lack of efficacy and side effects both contributing to the decision.
Pharmaceutical Commerce
AUGUST 9, 2024
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
European Pharmaceutical Review
AUGUST 9, 2024
Clinical data indicates that nipocalimab could provide benefit to foetuses, newborns and pregnant mothers at risk for a rare blood disorder. Findings from the Phase II UNITY study show that the treatment has potential to delay or prevent anaemia and the need for intrauterine blood transfusions in babies who are at high risk for haemolytic disease of the foetus and newborn (HDFN).
PharmaTech
AUGUST 9, 2024
AGX101 targets the cancer cells and vasculature of a tumor, and works to eliminate the tumor blood vessels, kill tumor cells capable of invasion or metastasis, and direct the immune system to attack the cancer.
PharmExec
AUGUST 9, 2024
As part of the acquisition of CN201, Curon is expected to receive an upfront payment of $700 million, with the opportunity to earn an additional $600 million in milestone payments linked to the drug's development and regulatory approval.
Pharmaceutical Commerce
AUGUST 9, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
AUGUST 9, 2024
Lymphir is the first therapy to target the IL-2 receptor in the treatment of relapsed or refractory cutaneous T-cell lymphoma and the first FDA-approved product for Citius Pharmaceuticals.
Scott Burrows
AUGUST 9, 2024
In my time as a keynote speaker, I have found that my story resonates with groups in high-risk occupations. About 6 months ago, I had the privilege of delivering a presentation on Business, Leadership, and Safety to leaders and supervisors at the Elevator Contractors Association Annual Meeting. The crowd was amazing, everyone was so lively and willing to learn.
Pharmaceutical Commerce
AUGUST 9, 2024
The transition to AI and machine learning was well underway long before ChatGPT burst onto the marketplace; however, organizations were, and still are, constrained by data challenges.
PharmExec
AUGUST 9, 2024
In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, talks about how they balance the need for profitability with the mission of providing treatments for rare diseases.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
AUGUST 9, 2024
MSD abandons another phase 3 TIGIT inhibitor trial, in another setback for the beleaguered cancer immunotherapy class
PharmExec
AUGUST 9, 2024
Approval of neffy marks a significant advancement in epinephrine delivery, offering a less painful alternative to traditional needle injections.
Pharmaceutical Commerce
AUGUST 9, 2024
Why the integration of AI-enabled solutions has the potential to boost patient support and engagement across numerous patient care settings.
PharmExec
AUGUST 9, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
287 
Let's personalize your content